Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Up 281.6% in June

Lonza Group Ag (OTCMKTS:LZAGY) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 31,620 shares, an increase of 281.6% from the June 15th total of 8,286 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 93,974 shares, the short-interest ratio is currently 0.3 days.

Lonza Group Stock Performance

Shares of OTCMKTS LZAGY traded up $0.40 during mid-day trading on Friday, reaching $72.63. 29,934 shares of the company’s stock were exchanged, compared to its average volume of 44,285. The firm has a 50-day moving average price of $63.99 and a two-hundred day moving average price of $65.47. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. Lonza Group has a 52 week low of $58.53 and a 52 week high of $73.85.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.